Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 - the public health challenges.
作者信息
Velavan Thirumalaisamy P, Ntoumi Francine, Kremsner Peter G, Lee Shui Shan, Meyer Christian G
机构信息
Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany; Vietnamese-German Center for Medical Research, VG-CARE, Hanoi, Vietnam; Faculty of Medicine, Duy Tan University, Da Nang, Vietnam.
Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany; Fondation Congolaise pour la Recherche Médicale, Brazzaville, Republic of Congo.
出版信息
Int J Infect Dis. 2023 Mar;128:307-309. doi: 10.1016/j.ijid.2023.01.024. Epub 2023 Jan 19.
Abstract
摘要
相似文献
1
Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 - the public health challenges.
Int J Infect Dis. 2023 Mar;128:307-309. doi: 10.1016/j.ijid.2023.01.024. Epub 2023 Jan 19.
2
Tracking SARS-CoV-2 variants during the 2023 flu season and beyond in Lebanon.
Virus Res. 2024 Jan 2;339:199289. doi: 10.1016/j.virusres.2023.199289. Epub 2023 Dec 2.
3
SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
J Med Virol. 2023 Mar;95(3):e28641. doi: 10.1002/jmv.28641.
4
The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties - an alarming global threat of a surge in COVID-19 cases again?
Int J Surg. 2023 Apr 1;109(4):1041-1043. doi: 10.1097/JS9.0000000000000246.
5
An updated review of epidemiological characteristics, immune escape, and therapeutic advances of SARS-CoV-2 Omicron XBB.1.5 and other mutants.
Front Cell Infect Microbiol. 2023 Dec 14;13:1297078. doi: 10.3389/fcimb.2023.1297078. eCollection 2023.
6
Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2.
Signal Transduct Target Ther. 2023 Mar 15;8(1):125. doi: 10.1038/s41392-023-01391-x.
7
Genomic Surveillance for SARS-CoV-2 Variants: Dominance of XBB Replacement - China, January-June 2023.
China CDC Wkly. 2024 Apr 12;6(15):324-331. doi: 10.46234/ccdcw2024.061.
8
Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.
Cell Host Microbe. 2023 Jan 11;31(1):9-17.e3. doi: 10.1016/j.chom.2022.11.012. Epub 2022 Nov 22.
9
A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates.
Proc Natl Acad Sci U S A. 2023 Mar 14;120(11):e2221713120. doi: 10.1073/pnas.2221713120. Epub 2023 Mar 10.
10
Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread.
Med Sci Monit. 2023 Feb 1;29:e939580. doi: 10.12659/MSM.939580.
引用本文的文献
1
Analysis of the prevalence, spread, and mutation patterns of SARS-CoV-2 variants: data from COVID-19 testing expansion strategy study in salvador, Northeast Brazil.
Sci Rep. 2025 Aug 29;15(1):31866. doi: 10.1038/s41598-025-17691-x.
2
One-Year Monitoring of the Evolution of SARS-CoV-2 Omicron Subvariants Through Wastewater Analysis (Central Italy, August 2023-July 2024).
Life (Basel). 2025 May 24;15(6):850. doi: 10.3390/life15060850.
3
Antiviral activity of an ACE2-Fc fusion protein against SARS-CoV-2 and its variants.
PLoS One. 2025 Jan 3;20(1):e0312402. doi: 10.1371/journal.pone.0312402. eCollection 2025.
4
Selective Pressure and Evolution of SARS-CoV-2 Lineages BF.7 and BQ.1.1 Circulating in Italy from July to December 2022.
Microorganisms. 2024 Apr 30;12(5):908. doi: 10.3390/microorganisms12050908.
5
A mini review of reinfection with the SARS-CoV-2 Omicron variant.
Health Sci Rep. 2024 Apr 10;7(4):e2016. doi: 10.1002/hsr2.2016. eCollection 2024 Apr.
6
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.
Vaccines (Basel). 2024 Jan 24;12(2):118. doi: 10.3390/vaccines12020118.
7
Spatiotemporal dynamics and epidemiological impact of SARS-CoV-2 XBB lineage dissemination in Brazil in 2023.
Microbiol Spectr. 2024 Mar 5;12(3):e0383123. doi: 10.1128/spectrum.03831-23. Epub 2024 Feb 5.
8
Systematic Genomic Surveillance of SARS-CoV-2 at Xiamen International Airport and the Port of Xiamen Reveals the Importance of Incoming Travelers in Lineage Diversity.
Viruses. 2024 Jan 17;16(1):132. doi: 10.3390/v16010132.
9
Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants.
NPJ Vaccines. 2023 Nov 20;8(1):177. doi: 10.1038/s41541-023-00776-x.
10
Outcomes and risk factors of SARS-CoV-2 omicron variant in B-cell lymphoma patients following CD19 targeted CAR-T therapy.
Cancer Med. 2023 Nov;12(22):20838-20846. doi: 10.1002/cam4.6657. Epub 2023 Nov 14.
本文引用的文献
1
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.
Lancet Infect Dis. 2023 Mar;23(3):278-280. doi: 10.1016/S1473-3099(23)00010-5. Epub 2023 Feb 3.
2
Covid-19: China stops counting cases as models predict a million or more deaths.
BMJ. 2023 Jan 3;380:2. doi: 10.1136/bmj.p2.
3
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
Cell. 2023 Jan 19;186(2):279-286.e8. doi: 10.1016/j.cell.2022.12.018. Epub 2022 Dec 14.
4
Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines.
Lancet Microbe. 2023 Mar;4(3):e131. doi: 10.1016/S2666-5247(22)00335-4. Epub 2022 Dec 6.
5
Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.
Cell Host Microbe. 2023 Jan 11;31(1):9-17.e3. doi: 10.1016/j.chom.2022.11.012. Epub 2022 Nov 22.
6
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation.
Lancet Infect Dis. 2022 Dec;22(12):1666-1668. doi: 10.1016/S1473-3099(22)00694-6. Epub 2022 Oct 31.
7
Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6.
N Engl J Med. 2022 Nov 17;387(20):1904-1906. doi: 10.1056/NEJMc2212117. Epub 2022 Oct 19.
8
Update on the omicron sub-variants BA.4 and BA.5.
Rev Med Virol. 2023 Jan;33(1):e2391. doi: 10.1002/rmv.2391. Epub 2022 Aug 26.
9
The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta.
J Travel Med. 2022 May 31;29(3). doi: 10.1093/jtm/taac037.
10
Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts.
Int J Infect Dis. 2022 Jan;114:268-272. doi: 10.1016/j.ijid.2021.11.040. Epub 2021 Dec 1.
Zotero 插件